- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01007175
Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis
September 3, 2013 updated by: Ablynx
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate
This primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic properties of multiple ascending doses of ATN-103 administered subcutaneously (below the skin) to Japanese subjects with active rheumatoid arthritis and on a stable background of methotrexate.
Some subjects will receive ATN-103 while other subjects will receive a placebo.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chiba, Japan
- Investigational site
-
Ehime, Japan
- Investigational site
-
Fukuoka, Japan
- Investigational site
-
Gunma, Japan
- Investigational site
-
Hyogo, Japan
- Investigational site
-
Kumamoto, Japan
- Investigational site
-
Kyoto, Japan
- Investigational site
-
Miyazaki, Japan
- Investigational site
-
Nagano, Japan
- Investigational site
-
Nagasaki, Japan
- Investigational site
-
Osaka, Japan
- Investigational site
-
Saga, Japan
- Investigational site
-
Saitama, Japan
- Investigational site
-
Tokyo, Japan
- Investigational site
-
Toyama, Japan
- Investigational site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meets the ACR 1987 revised criteria for classification of Rheumatoid Arthritis (RA).
- ACR functional class I through III.
- Active RA at the time of screening and at baseline consisting of = 6 swollen and = 6 tender joints at least.
- hs-CRP level = 8 mg/L.
- Must be receiving MTX for at least 12 wks, with a stable dose and route of MTX for at least 6 wks prior to the baseline and continuing on that dose for the duration of the study.
- The report of a chest x-ray performed within 12 wks before the screening documenting the absence of any evidence of malignancy, infection, or abnormalities suggestive of TB must be obtained and available in the subject's study file prior to baseline.
- All WOCBP must have a negative pregnancy test result at screening and baseline.
- All WOCBP who have sexual intercourse with a nonsurgically sterilized male partner must agree and commit to the use of the following highly effective forms of contraception for the duration of the study and for 8 wks after the last dose of investigational product.
- All male subjects who are biologically capable of fathering children must agree and commit to the use of a reliable method of birth control for the duration of the study and for 8 wks after the last dose of investigational product.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Presence of active infections or open cutaneous ulcers or any underlying disease that could predispose subjects to infections or history of serious infection within 4 wks before the baseline.
- A history or current evidence of latent or active TB, evidence of prior or currently active TB by chest X-ray, recent close contact with an individual with active TB, or a positive Mantoux tuberculin skin test.
- Other significant concurrent medical conditions at the time of the screening or baseline.
- Laboratory abnormalities at screening. Positive for HBsAg, HBcAb, and/or HepCAb. ALTand/or AST= 2 times the ULN or higher. Hemoglobin = 8.5 g/dL or lower. Platelet = 125,000 /mm³ or lower, or = 1,000,000 /mm³ or higher. WBC = 3500 /mm³ or lower. Serum creatinine= 2 mg/dL or higher.
- Any prior use of B cell-depleting therapy.
- Receipt within 24 wks before the baseline visit:
Any cytotoxic drugs. Leflunomide. Any investigational biological drug(s).
- Receipt within 12 wks before the baseline visit: Any biological drugs not listed under the exclusion criteria. Any surgical joint interventions (open or arthroscopic). Any investigational drugs (other than investigational biological drugs), procedures, or devices.
- Receipt within 8 wks before the baseline: Abatacept. Any type of TNF inhibitors not listed under the exclusion criteria.
- Receipt within 4 wks before the baseline: Any DMARDs, other than stable background MTX, or immunosuppressive drugs not listed under the exclusion criteria.
- Etanercept. IA hyaluronic acid injections. Any live (attenuated) vaccine.
- Receipt within 2 wks before the baseline: > 10 mg/day of oral prednisone or equivalent, or change in the dose of oral prednisone or its equivalent.
- IA, bolus IM, or IV treatment with corticosteroids. > 1 NSAID, change of dose of the NSAID, or NSAID use greater than the maximum recommended dose.
- Initiation of statins or dosage adjustment to a current statin. Change in the dose of folic acid.
- Known or suspected allergy to ATN-103, any type of TNF inhibitors, human immunoglobulin proteins, or other compounds related to these classes of medication.
- Current or history of psychiatric disease or alcohol or drug abuse that, in the opinion of the investigator, would interfere with the ability to comply with the study protocol or give informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
|
ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
|
Experimental: Cohort 2
|
ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
|
Experimental: Cohort 3
|
ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
|
Experimental: Cohort 4
|
ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
|
Experimental: Cohort 5
|
ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability will be evaluated on the basis of AEs, SAEs,(including injection site reactions and infections), physical examination findings, vital sign, measurements, immunogenicity assessments, early termination, and clinical laboratory test.
Time Frame: 20 weeks
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical efficacy for Rheumatoid Arthritis (RA) based on ACR responses, ACR-N, DAS 28 and EULAR response.
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Josefin-Beate Holz, Ablynx
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
November 2, 2009
First Submitted That Met QC Criteria
November 2, 2009
First Posted (Estimate)
November 3, 2009
Study Record Updates
Last Update Posted (Estimate)
September 4, 2013
Last Update Submitted That Met QC Criteria
September 3, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3242K1-2001
- B2271004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on ATN-103 10 mg q4wks
-
AblynxCompletedRheumatoid ArthritisUnited States, Russian Federation, Canada, Hungary, Japan, Serbia, South Africa, Switzerland
-
AblynxCompleted
-
Merck Sharp & Dohme LLCCompleted
-
PfizerCompleted
-
Idorsia Pharmaceuticals Ltd.Completed
-
Vedic Lifesciences Pvt. Ltd.Not yet recruitingUpper Respiratory Tract InfectionsIndia
-
Ferring PharmaceuticalsCompletedChronic Idiopathic ConstipationUnited States, Belgium, Canada, Czech Republic, Hungary, Poland, Slovakia, South Africa, Sweden, United Kingdom
-
Organon and CoCompletedHypercholesterolemia | Heterozygous Familial Hypercholesterolemia
-
Merck Sharp & Dohme LLCCompleted
-
Insmed IncorporatedCompletedNon-Cystic Fibrosis BronchiectasisUnited States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland